Genfit S.A.
EPA:GNFT.PA
5.39 (EUR) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Genfit S.A. |
Symbool | GNFT.PA |
Munteenheid | EUR |
Prijs | 5.39 |
Beurswaarde | 268,465,120 |
Dividendpercentage | 0% |
52-weken bereik | 2.9 - 5.86 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jean-Francois Mouney |
Website | https://www.genfit.com |
An error occurred while fetching data.
Over Genfit S.A.
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)